Skip to main content
Journal cover image

Post Autologous Transplant (autoHCT)Therapies in High Risk MM. Subgroup analysis of Phase III BMTCTN 0702 STAMINA: autoHCT Followed by Lenalidomide Maintenance(Len)(AM) vs auto HCT and Len and Bortezomib (BZ) and Dexamethasone Consolidation Len Maintenance(ACM) vs Tandem autoHCT Len Maintenance

Publication ,  Conference
Krishnan, A; Pasquini, M; Blackwell, B; Knust, K; Bashey, A; Devine, S; Efebera, Y; Ganguly, S; Gasparetto, C; Geller, N; Giralt, S; Koreth, J ...
Published in: Clinical Lymphoma Myeloma and Leukemia
February 2017

Duke Scholars

Published In

Clinical Lymphoma Myeloma and Leukemia

DOI

ISSN

2152-2650

Publication Date

February 2017

Volume

17

Issue

1

Start / End Page

e5 / e5

Publisher

Elsevier BV

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 3201 Cardiovascular medicine and haematology
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Krishnan, A., Pasquini, M., Blackwell, B., Knust, K., Bashey, A., Devine, S., … Stadtmauer, E. (2017). Post Autologous Transplant (autoHCT)Therapies in High Risk MM. Subgroup analysis of Phase III BMTCTN 0702 STAMINA: autoHCT Followed by Lenalidomide Maintenance(Len)(AM) vs auto HCT and Len and Bortezomib (BZ) and Dexamethasone Consolidation Len Maintenance(ACM) vs Tandem autoHCT Len Maintenance. In Clinical Lymphoma Myeloma and Leukemia (Vol. 17, pp. e5–e5). Elsevier BV. https://doi.org/10.1016/j.clml.2017.03.009
Krishnan, Amrita, Marcelo Pasquini, Beth Blackwell, Kristin Knust, Asad Bashey, Steven Devine, Yvonne Efebera, et al. “Post Autologous Transplant (autoHCT)Therapies in High Risk MM. Subgroup analysis of Phase III BMTCTN 0702 STAMINA: autoHCT Followed by Lenalidomide Maintenance(Len)(AM) vs auto HCT and Len and Bortezomib (BZ) and Dexamethasone Consolidation Len Maintenance(ACM) vs Tandem autoHCT Len Maintenance.” In Clinical Lymphoma Myeloma and Leukemia, 17:e5–e5. Elsevier BV, 2017. https://doi.org/10.1016/j.clml.2017.03.009.
Krishnan A, Pasquini M, Blackwell B, Knust K, Bashey A, Devine S, Efebera Y, Ganguly S, Gasparetto C, Geller N, Giralt S, Parameswaran H, Horowitz M, Koreth J, Landau H, McCarthy P, McClune B, Nelson C, Qazilbash M, Shah N, Vesole D, Vij R, Vogl DT, Somlo G, Stadtmauer E. Post Autologous Transplant (autoHCT)Therapies in High Risk MM. Subgroup analysis of Phase III BMTCTN 0702 STAMINA: autoHCT Followed by Lenalidomide Maintenance(Len)(AM) vs auto HCT and Len and Bortezomib (BZ) and Dexamethasone Consolidation Len Maintenance(ACM) vs Tandem autoHCT Len Maintenance. Clinical Lymphoma Myeloma and Leukemia. Elsevier BV; 2017. p. e5–e5.
Journal cover image

Published In

Clinical Lymphoma Myeloma and Leukemia

DOI

ISSN

2152-2650

Publication Date

February 2017

Volume

17

Issue

1

Start / End Page

e5 / e5

Publisher

Elsevier BV

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 3201 Cardiovascular medicine and haematology
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences